双靶点BRAF/MEK抑制剂治疗BRAF V600E突变原发性脑肿瘤:病例系列显示显著的临床与影像学反应及皮肤毒性降低
本文报告4例BRAF V600E突变的原发性脑肿瘤患者(毛细胞型星形细胞瘤、乳头型颅咽管瘤、神经节胶质瘤和多形性黄色星形细胞瘤),接受达拉非尼联合曲美替尼治疗。其中3例在治疗8周后获得近完全影像学反应和完全临床反应,1例神经节胶质瘤获RANO标准下的显著部分反应;1例颅咽管瘤患者加用曲美替尼后皮肤毒性完全消退。作者认为双靶向治疗是BRAF V600E原发性脑肿瘤有前景的治疗选择,且可能减轻皮肤毒性。
要点
- 4例BRAF V600E突变原发性脑肿瘤患者接受达拉非尼联合曲美替尼治疗。
- 毛细胞型星形细胞瘤、多形性黄色星形细胞瘤和乳头型颅咽管瘤患者治疗8周后达近完全影像学反应和完全临床反应。
- 神经节胶质瘤患者获RANO标准下的显著部分反应;加用曲美替尼后皮肤毒性完全消退。
核心结论
- 双靶点BRAF/MEK抑制剂治疗是BRAF V600E突变原发性脑肿瘤有前景的治疗选择,且与单药达拉非尼相比可能减轻皮肤毒性。
研究设计与样本
- 病例系列,共治疗4例BRAF V600E突变的原发性脑肿瘤患者,每例肿瘤类型不同(毛细胞型星形细胞瘤、乳头型颅咽管瘤、神经节胶质瘤和多形性黄色星形细胞瘤),均接受达拉非尼联合曲美替尼治疗。
主要发现
- 毛细胞型星形细胞瘤、多形性黄色星形细胞瘤和乳头型颅咽管瘤患者在治疗8周后获得近完全影像学反应和完全临床反应。
- 神经节胶质瘤患者获得RANO标准下的显著部分反应。
- 颅咽管瘤患者在开始达拉非尼治疗后2周内出现弥漫性疣状角化病,加用曲美替尼后2周内完全消退。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: BRAF V600E is a common oncogenic driver in a variety of primary brain tumors. Dual inhibitor therapy using dabrafenib (a selective oral inhibitor of several mutated forms of BRAF kinase) and trametinib (a reversible inhibitor of MEK1 and MEK2) has been used successfully for treatment of metastatic melanoma, anaplastic thyroid cancer, and other tumor types, but has been reported in only a few patients with primary brain tumors and none with pleomorphic xanthoastrocytoma. Here, the authors report on the substantial clinical response and reduction in cutaneous toxicity in a case series of BRAF V600E primary brain cancers treated with dual BRAF/MEK inhibitor therapy. METHODS: The authors treated 4 BRAF V600E patients, each with a different type of primary brain tumor (pilocytic astrocytoma, papillary craniopharyngioma, ganglioglioma, and pleomorphic xanthoastrocytoma) with the combination of dabrafenib and trametinib. RESULTS: The patients with pilocytic astrocytoma, pleomorphic xanthoastrocytoma, and papillary craniopharyngioma experienced near-complete radiographic and complete clinical responses after 8 weeks of therapy. A substantial partial response (by RANO [Response Assessment in Neuro-Oncology] criteria) was observed in the patient with ganglioglioma. The patient with craniopharyngioma developed dramatic, diffuse verrucal keratosis within 2 weeks of starting dabrafenib. This completely resolved within 2 weeks of adding trametinib. CONCLUSIONS: Dual BRAF/MEK inhibitor therapy represents an exciting treatment option for patients with BRAF V600E primary brain tumors. In addition to greater efficacy than single-agent dabrafenib, this combination has the potential to mitigate cutaneous toxicity, one of the most common and concerning BRAF inhibitor-related adverse events.
引用
- Bernstein A, Mrowczynski OD, Greene A, et al. Dual BRAF/MEK therapy in BRAF V600E-mutated primary brain tumors: a case series showing dramatic clinical and radiographic responses and a reduction in cutaneous toxicity. J Neurosurg. 2019. PMID: 31675726. doi:10.3171/2019.8.JNS19643
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。